ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for Cardiovascular stents and other implantable medical devices, has announced that Dr. Daljeet Singh Gambhir, Director of Cardiology and Chief Executive Officer of the Kailash Heart Institute, has been appointed to the Company’s Medical Advisory Board and will hold the position of Clinical Advisor to MIVT India.
In the position, Dr. Gambhir will oversee the next phases of MIVT’s research and human clinical studies in India as the Company steps up development and commercialization of its novel, biocompatible cardiovascular stents. Dr. Gambhir has been an active cardiologist for nearly 25 years and is considered one of the most influential professionals in the field of interventional cardiology in India.
“It is an honor to welcome Dr. Gambhir as a medical advisor during this time of unprecedented growth in MIVT’s history,” said Dr. Mark Landy, President of MIV Therapeutics. “We believe that his extensive experience will play a key roll in the development of our next generation stents as we move towards clinical trials.”
MIVT is developing a next-generation cardiovascular stent technology being designed to provide substantial health and safety benefits and outcomes over previous generations of drug-eluding stents. MIVT has developed a new line of both ultra-thin and drug-carrying cardiovascular stent coatings based on its proprietary hydroxyapatite (HAp) technology.
“The international medical community has been asking for a better, more reliable and more effective stent for some time now and I believe that MIV’s biocompatible coatings may help us meet that demand,” said Dr. Gambhir. “I look forward to working with MIV and hope to play a key role in the development of their promising technology.”
Dr. Gambhir has been recognized as a pioneer of non-surgical interventional techniques and has performed nearly 10,000 coronary angioplasties in all types of lesions, vessels and clinical conditions. He also established the facility for Radiation Therapy for the treatment of coronary restenosis at G.B. Pant Hospital in New Delhi.
About MIV Therapeutics Inc.
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage.
For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.